Loading
A phase 2 trial of Fulzerasib in Colorectal cancer, run by Zhejiang University, now recruiting.
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases is a phase 2 interventional study registered as NCT07581912 by Zhejiang University, with 40 participants planned, started 2026-04-30 and due to reach its primary completion in 2028-12. Interventions recorded: fulzerasib; cetuximab N01. Conditions recorded: Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01.
Linked to the drug Fulzerasib because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulzerasib and the tag pipeline.
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/